Focal adhesion kinase inhibitor as a therapeutic agent in diabetes
AssigneeUniversity of Pittsburgh—Of the Commonwealth System of Higher Education
InventorsFarzad Esni, Jing Hu
Life of this patent
Estimating the term…
Abstract
It is disclosed herein that a FAK inhibitor induces conversion of acinar cells into beta cells. Methods are provided for increasing beta cell proliferation by administering an effective amount of a FAK inhibitor to a subject in need thereof. Methods are also provided for treating a subject with diabetes or at risk of developing diabetes, comprising administering to the subject a therapeutically effective amount of a FAK inhibitor.
Claims22
A method for treating a subject with type 2 diabetes, comprising:
- administering to the subject a therapeutically effective amount of a focal adhesion kinase (FAK) inhibitor, wherein the FAK inhibitor is PF-562271, thereby treating the type 2 diabetes in the subject.
A method for treating a subject with type 2 diabetes, comprising:
- selecting the subject with type 2 diabetes for treatment,
- administering to the subject a therapeutically effective amount of PF-562271, and
- subsequently detecting acinar-derived beta cells in the subject,
- thereby treating the type 2 diabetes in the subject.
A method for treating a subject with type 2 diabetes, comprising:
- selecting the subject with type 2 diabetes for treatment, and
- increasing an amount of acinar-derived beta cells in the subject by administering a therapeutically effective amount of PF-562271 to the subject,
- thereby treating the type 2 diabetes in the subject.
Dependencies are inferred from the claim text.